Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK
- Hui Li1,
- Xi Wang1,
- Yiqing Mao1,
- Ruobi Hu1,
- Wei Xu1,
- Zhen Lei4,
- Na Zhou1,
- Ling Jin1,
- Tingting Guo1,
- Zhixin Li5,
- David M Irwin3,
- Gang Niu†2Email author and
- Huanran Tan†1Email author
© Li et al.; licensee BioMed Central Ltd. 2014
Received: 5 December 2013
Accepted: 17 January 2014
Published: 22 January 2014
The liver-specific glucokinase knockout (gckw/–) mouse experiences long-term hyperglycemia and insulin resistance. This study was designed to evaluate the functional and structural changes in the myocardium of 60 week-old gckw/– mice, and to investigate the effect of rosiglitazone on the myocardium in this model.
60 week-old gckw/– mice were randomly divided into 3 groups: gckw/–, gckw/– mice treated with insulin (1 U/kg) and gckw/– mice treated with rosiglitazone (18 mg/kg). Insulin or rosiglitazone treatment was for 4 weeks. Gckw/w litermates were used as controls. Echocardiography, electrocardiogram, biochemical, histopathological, ultrastructural, real time PCR and Western blot studies were performed to examine for structural and functional changes.
Long-term liver-specific gck knockout in mice elicits hyperglycaemia and insulin resistance. Compared to age matched gckw/w mice, 60 week-old gckw/– mice showed decreased LV internal dimension, increased posterior wall thickness, lengthened PR and QRS intervals, up-regulated MLC2 protein expression, decreased SOD activity, increased MDA levels and up-regulated Cyba mRNA. Morphological studies revealed that there was an increase in the amount of PAS and Masson positively stained material, as did the number and proportion of the cell occupied by mitochondria in the gckw/– mice. Western blot analysis revealed that the levels of the insulin receptor, Akt, phosphorylated AMPK beta and phosphorylated ACC were reduced in gckw/– mice. These effects were partly attenuated or ablated by treatment with rosiglitazone.
Our results indicate that changes in the myocardium occur in the liver-specific glucokinase knockout mouse and suggest that reduced glucokinase expression in the liver may induce diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK protein levels. Rosiglitazone treatment may protect against diabetic cardiomyopathy by altering the levels of a set of proteins involved in cardiac damage.
KeywordsLiver-specific glucokinase knockout Diabetic cardiomyopathy Rosiglitazone Insulin receptor AMPK
Diabetic cardiomyopathy (DCM) is defined as structural and functional changes in the myocardium, which are independent of hypertension, chronic artery disease or any other known cardiac diseases, and are caused by metabolic and cellular abnormalities induced by diabetes mellitus (DM). One of the most important structural hallmarks of DCM is cardiac hypertrophy [1, 2]. Hyperglycemia has been viewed as the pivotal pathogenetic factor for the development of DCM. In fact, it can cause abnormalities at the cardiac myocyte level, eventually leading to functional and structural abnormalities, including systolic and diastolic dysfunction, as well as cardiac hypertrophy and myocardial fibrosis . However, other factors seem to be involved in the evolution of the disease, including hyperinsulinemia, insulin resistance, oxidative stress, inflammation, endothelial dysfunction and apoptosis [1, 2, 4]. Animal models have been used to study the mechanisms underlying DCM [5–8]. In some animal models of DCM, drug treatment, or the effects of genetic mutation often leads to obesity and diabetes. All of these models have limitations and none are a perfect phenocopy of the human condition .
Maturity-onset diabetes of the young (MODY) is a clinically heterogeneous group of disorders and accounts for about 2%–5% of all diabetic patients . To date, five proteins have been identified whose genetic absence or impairment causes MODY, the enzyme glucokinase (GCK/MODY2) and four transcription factors: hepatocyte nuclear factor (HNF) 4α/MODY1, HNF-1α/MODY3, insulin promoter factor 1/MODY4 and HNF-1β/MODY5. MODY2 is one of the most prevalent subtypes of MODY and is associated with mutations in the glucokinase gene on Chromosome 7p and is characterized by chronic mild hyperglycemia, with an onset usually before the age of 25 [11, 12]. Little data is available on MODY2, as only a few mouse models have been developed [10, 13, 14]. Bali et al.  used homologous recombination in mouse embryonic stem cells to assess the effects of disrupting GCK function in both β-cells and hepatocytes as an animal model for MODY2. A liver-specific glucokinase knockout mouse has been constructed as a model for the liver-specific role of glucokinase in MODY2, independent of its function in regulating insulin secretion in pancreatic β-cells. Liver-specific glucokinase knockout mice were generated using the Cre-loxP gene targeting strategy, and the primary effects of the deletion of the gene have been evaluated .
The nuclear transcription factor peroxisome proliferator activated receptor γ (PPARγ) is a key regulator in adipogenesis. Thiazolidinediones, agonists of PPARγ, are an established and effective treatment for patients with type 2 diabetes . Recently, there has been some controversy regarding an increase in cardiovascular events, including myocardial infarction and congestive heart failure, in humans with the use of the PPARγ agonist, rosiglitazone [17, 18].
The aim of this study was to investigate the functional and structural changes in the myocardium that result from long-term reduced liver gck expression in our mouse liver-specific gckw/– MODY2 model and to determine whether rosiglitazone or insulin can reverse these changes in these mice.
A protocol for these experiments, following the “Guidelines for Animal Experiments”, was approved by the Peking University Health Science Center. Liver-specific gck knockout mice were previously generated by our lab . Liver-specific gck knockout mice (gckw/–) were randomly divided into 3 groups: untreated (gckw/–, n = 9), gckw/– treated with insulin (gckw/– + Ins, n = 9) and gckw/– treated with rosiglitazone (gckw/– + RSG, n = 9). Wild-type littermates (gckw/w, n = 9) were used as controls. Insulin (1 U/kg/day) was administrated to the gckw/– mice by subcutaneous injection for 4 weeks (gckw/– + Ins). Rosiglitazone (18 mg/kg/day) was administrated to the gckw/– mice by gavage for 4 weeks (gckw/– + RSG).
Assay of biochemistry parameters
Transthoracic echocardiography was performed on pentobarbital anesthetized mice at rest using a high-resolution imaging system for small animals (Vevo 770, VisualSonics, Toronto, Canada), equipped with a high-frequent ultrasound probe (RMV-707B). Parasternal long-axis and short-axis views were acquired. Left ventricular (LV) dimensions and wall thicknesses were determined from parasternal short axis M-mode images. Ejection fraction (EF) and fractional shortening (FS) were calculated using the Vevo770 software. The final data represent the averaged values of 3–6 cardiac cycles.
Surface electrocardiographic (ECG) recordings were obtained from conscious mice. For analysis of ECGs, the onsets and offsets of the P, Q, R, S, and T waves were determined by measuring the earliest (onset) and the latest (offset) times from lead II.
Sodium dodecyl sulfate-polyacrylamidegel electrophoresis (SDS-PAGE) and Western blot to measure myocardium myosin light chain (MLC2), insulin receptor β (IRβ), Akt, adenosine 5′-monophosphate (AMP)-activated protein kinase alpha (AMPKα), p-AMPKα, AMPKβ1/2, p-AMPKβ1, acetyl-CoA carboxylase (ACC) and p-ACC were performed. Heart tissue was homogenized and protein was quantified using the Bradford method. Sixty micrograms of protein was separated on SDS-PAGE. Separated proteins were transferred by electroelution onto PVDF paper (Millipore, Billerica, USA). Blots were probed with rabbit antibodies to insulin receptor β, Akt, AMPKα, Phospho-AMPKα (Thr172), AMPKβ1/2, Phospho-AMPKβ1 (Ser108), ACC and Phospho-ACC (Ser79). All antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA) and used at 1:1000 dilution with incubation overnight at 4°C. Anti-mouse MLC2 antibody was procured from Santa Cruz Biotechnology (Dallas, USA). Antibody binding was detected after incubation with appropriate secondary antibodies conjugated with HRP, with the membrane-bound antibodies visualized by luminal chemiluminescence ChemiDoc XRS (Bio-Rad, Hercules, CA, USA).
Reverse transcription and real-time PCR
List of primers used in this study
Prepared heart slides were stained with periodic acid-Schiff’s reagent (PAS) for glycogen and evaluated by light microscopy. The glycogen content of the myocardial tissue sections was expressed as the relative area of positive PAS-stained tissue (purple red-stained glycogen) to the total tissue area using Image-Pro Plus 6 (Media Cybernetics, Rockville, USA).
Mouse cardiac tissue was first fixed on Bouin’s fixative and stained with Weigert’s hematoxylin and Biebrich scarlet-acid fuchsin (Sigma, Milwaukee, USA), followed by treatment with phosphomolybdic–phosphotungstic acid solution (Sigma) and staining by methyl blue and Mayer’s Hematoxylin and Eosin. The extent of fibrosis in the myocardial tissue sections was quantified using Image-Pro Plus 6 (Media Cybernetics, Rockville, USA) as the relative area of positive stained area (blue–green fibrosis) normalized to the total tissue area.
Samples were collected from freshly excised left ventricular myocardium and processed as described previously . The proportion of the cell volume occupied by mitochondrial (volume density) and the number of mitochondria were analyzed in a blinded fashion by the point counting method using Image-Pro Plus 6 (Media Cybernetics, Rockville, USA). Mitochondrial volume density was quantified as the relative area of mitochondrial area normalized to the total cell area.
SOD activity and MDA levels
Superoxide dismutase (SOD) activities and malondialdehyde (MDA) levels in the myocardial tissues and serum were determined using commercially available kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
Results are shown as means ± SD. Differences between the control and experimental groups were evaluated by one-way (ANOVA; SPSS 13.0 for Windows, SPSS Inc., Chicago, IL, USA). P values less than 0.05 were considered to be statistically significant.
Effects of the liver-specific gck gene knockout on glucose homeostasis and insulin resistance in mice
Left ventricle internal dimension and posterior wall thickness is deteriorated in the liver-specific gck gene knockout mouse
Echocardiographic measurements (M-mode) in gck w/– and gck w/w mice (n = 3)
gckw/– + Ins
gckw/– + RSG
2.55 ± 0.15*
2.06 ± 0.16#
2.54 ± 0.15*
2.50 ± 0.12*
0.84 ± 0.10*
1.03 ± 0.06#
1.27 ± 0.10#*
1.08 ± 0.07#
1.15 ± 0.05*
0.84 ± 0.08#
0.86 ± 0.07*
0.89 ± 0.11*
1.14 ± 0.14*
1.54 ± 0.17#
1.90 ± 0.09#*
1.74 ± 0.03#*
0.93 ± 0.09
0.83 ± 0.21
1.19 ± 0.09#*
0.94 ± 0.06
1.12 ± 0.42
1.48 ± 0.15
1.76 ± 0.05*
1.48 ± 0.39
86.87 ± 1.97
90.62 ± 2.31
94.08 ± 1.23*
93.23 ± 2.07*
54.49 ± 2.58
59.31 ± 3.52
66.19 ± 2.59#*
64.61 ± 4.01#*
PR and QRS intervals are lengthened in the liver-specific gck knockout mouse
ECG parameters in gck w/– and gck w/w mice (n = 6)
gckw/– + Ins
gckw/– + RSG
613.9 ± 51.47
537.9 ± 65.6
592.6 ± 87.3
505.3 ± 39.9
9.22 ± 1.64
14.82 ± 7.68
8.06 ± 1.96
10.82 ± 1.36
38.28 ± 2.31*
44.77 ± 7.46#
36.75 ± 6.29*
38.41 ± 0.67*
8.54 ± 1.35**
13.35 ± 3.28##
8.37 ± 1.87*
9.77 ± 0.71*
18.06 ± 1.56
21.04 ± 2.28
16.98 ± 0.60
16.13 ± 1.89
58.10 ± 3.83
63.28 ± 10.73
53.36 ± 5.81
46.92 ± 6.97
Liver-specific gck gene knockout mice have increased myocardium MLC2 protein levels
Liver-specific gck gene knockout aggravates oxidative stress in mouse serum and myocardium tissue
Cardiac fibrosis was increased in the liver-specific gck knockout mouse
Liver-specific gck gene knockout augments mitochondrial volume density and number
Liver-specific gck gene knockout impairs the levels of the insulin receptor and Akt
Liver-specific gck gene knockout reduces AMPKβ and ACC phosphorylation
MODY2 in humans is characterized by mild but chronic hyperglycemia, with some MODY2 patients displaying peripheral insulin resistance, but diabetes-associated macro- and micro-vascular complications, overweight, and dyslipidemia are uncommon [22, 23]. Patients can usually manage their blood glucose levels by diet and exercise alone . The liver-specific gck knockout mice (gckw/–) appear normal at birth, with measurement of plasma insulin, triglyceride, cholesterol, ALT, and AST showing no difference compared with wild-type mice at up to 6 weeks of age . These parameter are similar to those observed in MODY2 patients. Fasting blood glucose levels in these mice increase with age and these mice spontaneously develop hyperglycemia after 6 weeks of age with impaired glucose tolerance and a decreased accumulation of hepatic glycogen . These mice however, do not exhibit signs of obesity with aging . No evidence of autoimmunity in the pancreatic islets is exhibited by these knockout mice . The gckw/– mouse, thus, may serve as a model of human MODY2 diabetes as it is associated with mild hyperglycemia and insulin resistance without hypoinsulinemia. These mice (gckw/– mice) were used to investigate the functional and structural changes in the myocardium that result from long-term (60 weeks) reduced liver gck expression (yielding mild hyperglycemia) followed by 4 weeks with or without treatment with insulin or rosiglitazone.
Diabetic cardiomyopathy describes diabetes-associated changes in myocardial structure and function. HOMA-IR is based on the dynamic interaction between glucose and insulin output and is a well-documented clinical representation of insulin resistance when compared to the gold standard reference, the euglycemic clamp . In several studies, an association between diabetic cardiomyopathy and HOMA-IR has been found. The HOMA index is an independent determinant of LV diastolic function . Insulin resistance has been correlated with increased left ventricular mass and risk of heart failure . In this study, we found that in gckw/– mice both serum glucose levels and insulin resistance were dramatically elevated compared with the control group (gckw/w mice). It has been demonstrated that the impairment of glucose homeostasis is able to affect the severity of heart disease.
MLC2 is part of the myosin complex, a hexameric complex of two heavy chains and four light chains, predominantly expressed in cardiac ventricle muscle . The regulatory light chains of the myosin complex, MLC2, can be phosphorylated leading to a conformational change, which consequently affects muscle contraction . Mutations in the human MLC2 gene have been associated with hypertrophic cardiomyopathy and lack of MLC2 in mice is embryonic lethal due to cardiac dysfunction that results in heart failure, a massive cardiac enlargement, wall thinning, and abnormalities in myofibril assembly . In this study, we found that in gckw/– mice the level of MLC2 protein expression was dramatically elevated compared with the control group (gckw/w mice). Koka et al.  revealed a coordinated down regulation of cytoskeletal contractile proteins such as myosin heavy-chainα (αMHC), and an up-regulation of MLC2 in diabetic mice, a result consistent with our results. The specific mechanism underlying these changes is unclear and we hypothesized that an increase in MLC2 levels may lead to myocardial hypertrophy by interfering with the assembly of myofibrils.
In several studies, an association between diabetic cardiomyopathy and cardiac hypertrophy, increased myocardial stiffness and reduced chamber compliance has been found . Clinical studies have demonstrated that diabetic cardiomyopathy is manifested with left ventricular hypertrophy associated with systolic/diastolic dysfunction and cardiac fibrosis in diabetic patients . In the present study, we observed cardiac hypertrophy in the gckw/– mouse, which was observed as an increase in the left ventricular wall thickness, a decrease of the left ventricular internal dimension, longer PR and QRS intervals, and increased myocardium MLC2 protein levels. Treatment with rosiglitazone results in PR and QRS intervals (Table 3), and MLC2 protein levels (Figure 3) being restored to wild-type levels, however, LVPW (Table 2) worsened after treatment with insulin or rosiglitazone.
A significant increase in collagen deposition around the intramural cardiacvessels and between myofibrils in heart biopsies from diabetic patients has been found . The PAS reaction is due to the accumulation of glycoprotein in the myocardium, which leads to interstitial fibrosis. Formation of glycoprotein has been suggested to be due to the increased formation of glucose-derived aldehydes, giving rise to so-called advanced glycation end products (AGEs) . The accumulation of glycoprotein increases myocardial stiffness by cross-linking. As seen in our study, reduced gck expression in the liver had an unfavorable effect on cardiac morphology and lead to the accumulation of collagen (Masson positive material) and glycoproteins (PAS positive material) in the myocardium (Figure 5). Glycoproteins increase intracellular oxidative stress, which contributes to additional cell damage. Oxidative stress is associated with mitochondrial damage and plays an important role in the development of diabetic cardiomyopathy .
Hyperglycemia-induced impairment of redox balance is considered to be a key trigger of diabetic complications, through the up-regulated generation of reactive oxygen species (ROS) , together with an impaired ability of the endogenous antioxidant defense system to remove them . The heart is particularly susceptible to oxidative damage, as it possesses lower levels of endogenous antioxidants in comparison to other organs. Cyba and Cybb are essential subunits of the NADPH oxidase, an enzyme considered to be a major source of O2˙- in cardiac cells catalyzing the one-electron reduction of oxygen using NADH or NADPH as the electron donor . Recent evidence suggests that NADPH oxidase derived superoxide is a key trigger of mitochondrial dysfunction and up regulated mitochondrial superoxide generation . SOD is one of the most important physiological antioxidants against free radicals and functions to prevent subsequent lipid peroxidation. Lipid peroxidation, which is a normal phenomenon that occurs continuously at lowlevels in every individual, is the most common consequence of oxidative stress. MDA is the end product of lipid peroxidation and is toxic to cells and cell membranes. Hyperglycemia contributes to the activation of free radicals and leads to tissue damage in different organs, such as endothelial dysfunction, hypertrophy and fibrosis . In the present study, we found that the MDA content and Cyba mRNA expression levels were significantly higher in gckw/– mice than in gckw/w control mice, which is concordant with the finding of significantly decreased SOD activity in the gckw/– mice. These results suggest that reduced liver gck expression may lead to a decreasein the antioxidant capacity of the diabetic myocardium, contributing significantly to oxidative stress and the resulting myocardial damage.
At the same time, our study showed that the mitochondrial volume density and number were increased in the gckw/– mice compared to gckw/w mice (Figure 6). After treatment with rosiglitazone or insulin, these parameters were restored to more normal values. Mitochondria are the center of fatty acid and glucose metabolism and thus are highly likely to be impacted by impaired metabolism associated with diabetes. Increased number and size of >mitochondria might be an adaptive response to hyperglycemia . It has recently been shown that insulin resistance drives the cardiac mitochondrial biogenesis regulatory program via PPARα, where activation was increased due to increased fat uptake and oxidation [40, 41]. The liver-specific glucokinase knockout mouse experienced long-term hyperglycemia, which results in decreased insulin receptor levels and ultimately leading to insulin resistance and attenuated glucose uptake . Insulin resistance drives the cardiac mitochondrial biogenesis regulatory program, which lead to increased mitochondrial volume density and number . Increased oxidative phosphorlyation and impairment in the electron transport chain contribute to increased ROS and superoxide (O2˙-) production . These changes cause morphological and functional abnormalities in cardiac tissue, thus suggesting that oxidative stress might be the unifying factor for the damaging effects of hyperglycemia .
The molecular signaling pathways implicated in myocardial damage in gckw/– mice have not been fully resolved. We demonstrate that the cardiac insulin receptor and Akt protein levels, key factors of the IR-PI3K-Akt pathway, were reduced in gckw/– mice, but were restored to wild-type levels by insulin or rosiglitazone treatment. The IR-PI3K-Akt pathway induces a hypertrophic response associated with cardioprotection , in which cardiac structure and function are preserved. Based on our observations, we postulate that prolonged exposure to increased levels of serum glucose depresses protectiveIR-PI3K-Akt signaling. Preservation of insulin receptor and Akt levels in the rosiglitazone-treated diabetic myocardium might thereby confer protection against pathological cardiac hypertrophy.
Metabolic disorders play major roles in the pathogenesis of diabetic cardiomyopathy. AMPK is a central regulator for glucose and fatty acid metabolism in mammalian cells, which acts as anenergy sensor, responding to a rise in AMP levels by increasing ATP generating pathways and reducing ATP-consuming pathways . AMPK is a heterotrimeric complex composed of a catalytic α subunit and regulatory β and γ subunits. Phosphorylation at Ser108 of theβ1 subunit seems to be required for the activation of AMPKenzyme. AMPK phosphorylation inhibits fatty acid and cholesterol synthesis and gluconeogenesis in the liver and stimulates fatty acid uptake and oxidation, glucose uptake, and mitochondrial biogenesis in skeletal muscle .
ACC is a cytosolic enzyme that catalyzes the carboxylation of cytosolic acetyl-CoA to form malonyl-CoA, which is the pivotal step of the fatty acid synthesis pathway . ACCβ is the major isoform in heart. We demonstrated that the levels of phosphorylated AMPK and ACC were dramatically lower in gckw/– mice, but only p-ACC was restored to wild-type levels with rosiglitazone treatment. It has previously been reported that AMPK regulates ACC phosphorylation . Phosphorylation by AMPK inhibits the enzymatic activity of ACC, and in turn malonyl-CoA levels . These results suggest that the fatty acid synthesis pathway may be enhanced in the myocardium of gckw/– mice, due to a reduction in ACC phosphorylation. The accumulation of fatty acid also causes a pathological ROS accumulation, which leads to damage in cardiomyocytes. It has been hypothesized that the dysregulation of the AMPK/ACC fuel-sensing and signaling network is a key factor in the development of insulin resistance and cardiac hypertrophy .
Maturity-onset diabetes of the young
Peroxisome proliferator activated receptor γ
Intraperitoneal glucose tolerance test
Homeostasis model assessment
Myocardium myosin light chain
Adenosine 5'-monophosphate (AMP)-activated protein kinase
Left ventricle internal dimension during diastole; LVID
Left ventricle internal dimension during systole; LVPW
Left ventricle posterior wall thickness during diastole; LVPW
Left ventricle posterior wall thickness during systole
Cytochrome b-245 alpha
Cytochrome b-245 beta.
This study was supported by grants from the National Natural Science Foundation of China (NSFC) Grant Number 81102484 and 30772603, National Key Technologies R&D Program (Grant Numbers 2006BAF07B01, 2009BAK61B01, 2009BAK61B04, and 2012BAK25B01), and a grant from the National Science Foundation of China – Canadian Institutes of Health Research (NSFC-CIHR) China-Canada Joint Health Research Initiative (Grant Numbers 81061120525 and CCI-109605).
- Voulgari C, Papadogiannis D, Tentolouris N: Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag. 2010, 6: 883-903.PubMed CentralView ArticlePubMed
- Boudina S, Abel ED: Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010, 11: 31-39. 10.1007/s11154-010-9131-7.PubMed CentralView ArticlePubMed
- Murarka S, Movahed MR: Diabetic cardiomyopathy. J Card Fail. 2010, 16: 971-979. 10.1016/j.cardfail.2010.07.249.View ArticlePubMed
- Nunes S, Soares E, Pereira FC, Reis F: The role of inflammation in diabetic cardiomyopathy. Int J Infereron Cytokine Mediator Res. 2012, 4: 59-73.
- Fredersdorf S, Thumann C, Zimmermann WH, Vetter R, Graf T, Luchner A, Riegger GA, Schunkert H, Eschenhagen T, Weil J: Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Cardiovasc Diabetol. 2012, 11: 57-10.1186/1475-2840-11-57.PubMed CentralView ArticlePubMed
- Hou L, Lian K, Yao M, Shi Y, Lu X, Fang L, He T, Jiang L: Reduction of n-3PUFAs, specifically DHA and EPA, and enhancement of peroxisomal beta oxidation in type 2 diabetic rat heart. Cardiovasc Diabetol. 2012, 11: 126-10.1186/1475-2840-11-126.PubMed CentralView ArticlePubMed
- Aragno M, Mastrocola R, Ghé C, Arnoletti E, Bassino E, Alloatti G, Muccioli G: Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol. 2012, 11: 129-10.1186/1475-2840-11-129.PubMed CentralView ArticlePubMed
- Nunes S, Soares E, Fernandes J, Viana S, Carvalho E, Pereira FC, Reis F: Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide over expression seems to be the best marker. Cardiovasc Diabetol. 2013, 12: 44-10.1186/1475-2840-12-44.PubMed CentralView ArticlePubMed
- Bugger H, Abel ED: Rodent models of diabetic cardiomyopathy. Dis Model Mech. 2009, 2: 454-466. 10.1242/dmm.001941.View ArticlePubMed
- Toye AA, Moir L, Hugill A, Bentley L, Quarterman J, Mijat V, Hough T, Goldsworthy M, Haynes A, Hunter AJ, Browne M, Spurr N, Cox RD: A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene. Diabetes. 2004, 53: 1577-1583. 10.2337/diabetes.53.6.1577.View ArticlePubMed
- Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001, 345: 971-980. 10.1056/NEJMra002168.View ArticlePubMed
- Froguel P, Velho G: Molecular genetics of maturity-onset diabetes of the young. Trends Endocrinol Metab. 1999, 10: 142-146. 10.1016/S1043-2760(98)00134-9.View ArticlePubMed
- Inoue M, Sakuraba Y, Motegi H, Kubota N, Toki H, Matsui J, Toyoda Y, Miwa I, Terauchi Y, Kadowaki T, Shigeyama Y, Kasuga M, Adachi T, Fujimoto N, Matsumoto R, Tsuchihashi K, Kagami T, Inoue A, Kaneda H, Ishijima J, Masuya H, Suzuki T, Wakana S, Gondo Y, Minowa O, Shiroishi T, Noda T: A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program. Hum Mol Genet. 2004, 13: 1147-1157. 10.1093/hmg/ddh133.View ArticlePubMed
- van Bürck L, Blutke A, Kautz S, Rathkolb B, Klaften M, Wagner S, Kemter E, de Hrabé Angelis M, Wolf E, Aigner B, Wanke R, Herbach N: Phenotypic and pathomorphological characteristics of a novel mutant mouse model for maturity-onset diabetes of the young type 2 (MODY 2). Am J Physiol Endocrinol Metab. 2010, 298: E512-E523. 10.1152/ajpendo.00465.2009.View ArticlePubMed
- Zhang YL, Tan XH, Xiao MF, Li H, Mao YQ, Tan HR: Establishment of liver specific glucokinase gene knockout mice: a new animal model for screening anti-diabetic drugs. Acta Pharmacol Sin. 2004, 25: 1659-1665.PubMed
- Hemmeryckx B, Hoylaerts MF, Gallacher DJ, Rong Lu H, Himmelreich U, D’hooge J, Swinnen M, Lijnen HR: Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?. Eur J Pharmacol. 2013, 700: 23-31. 10.1016/j.ejphar.2012.11.062.View ArticlePubMed
- Nissen SE, Wolski K: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010, 170: 1191-1201.View ArticlePubMed
- Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010, 304: 411-418. 10.1001/jama.2010.920.View ArticlePubMed
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.View ArticlePubMed
- Bugger H, Riehle C, Jaishy B, Wende AR, Tuinei J, Chen D, Soto J, Pires KM, Boudina S, Theobald HA, Luptak I, Wayment B, Wang X, Litwin SE, Weimer BC, Abel ED: Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J Molec Cell Cardiology. 2012, 52: 1019-1026. 10.1016/j.yjmcc.2012.02.001.View Article
- England J, Loughna S: Heavy and light roles: myosin in the morphogenesis of the heart. Cell Mol Life Sci. 2013, 70: 1221-1239. 10.1007/s00018-012-1131-1.PubMed CentralView ArticlePubMed
- Velho G, Froguel P: Genetic, metabolic and clinical characteristics of maturity onset diabetes of the young. Eur J Endocrinol. 1998, 138: 233-239. 10.1530/eje.0.1380233.View ArticlePubMed
- Velho G, Vaxillaire M, Boccio V, Charpentier G, Froguel P: Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q. Diabetes Care. 1996, 19: 915-919. 10.2337/diacare.19.9.915.View ArticlePubMed
- Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K: Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J. 2001, 48: 81-86. 10.1507/endocrj.48.81.View ArticlePubMed
- Shigematsu Y, Hamada M, Nagai T, Nishimura K, Inoue K, Suzuki J, Ogimoto A, Higaki J: Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol. 2011, 58: 18-25. 10.1016/j.jjcc.2011.03.001.View ArticlePubMed
- Vecoli C, Andreassi MG, Liga R, Colombo MG, Coceani M, Carpeggiani C, L’Abbate A, Neglia D: T(-786)C polymorphism of the endothelial nitric oxide synthase gene is associated with insulin resistance in patients with ischemic or non ischemic cardiomyopathy. BMC Med Gene. 2012, 13: 92-98.View Article
- Weterman MA, Barth PG, van Spaendonck-Zwarts KY, Aronica E, Poll-The BT, Brouwer OF, van Tintelen JP, Qahar Z, Bradley EJ, de Wissel M, Salviati L, Angelini C, van den Heuvel L, Thomasse YE, Backx AP, Nürnberg G, Nürnberg P, Baas F: Recessive MYL2 mutations cause infantile type I muscle fibre disease and cardiomyopathy. Brain. 2013, 136: 282-293. 10.1093/brain/aws293.View ArticlePubMed
- Koka S, Xi L, Kukreja RC: Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. Basic Res Cardiol. 2012, 107: 249-253.View ArticlePubMed
- Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB: The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol. 2001, 37: 1943-1949. 10.1016/S0735-1097(01)01230-X.View ArticlePubMed
- Poornima IG, Parikh P, Shannon RP: Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006, 98: 596-605. 10.1161/01.RES.0000207406.94146.c2.View ArticlePubMed
- Teupe C, Rosak C: Diabetic cardiomyopathy and diastolic heart failure – difficulties with relaxation. Diabetes Res Clin Pract. 2012, 97: 185-194. 10.1016/j.diabres.2012.03.008.View ArticlePubMed
- Christopher CL, Mathuram LN, Genitta G, Cyrus I, Sundar SJ: O mega-3 polyunsaturated fatty acids inhibit the accumulation of PAS-positive material in the myocardium of STZ-diabetic wistar rats. Int J Cardiol. 2003, 88: 183-190. 10.1016/S0167-5273(02)00393-5.View ArticlePubMed
- Watanabe K, Thandavarayan RA, Harima M, Sari FR, Gurusamy N, Veeraveedu PT, Mito S, Arozal W, Sukumaran V, Laksmanan AP, Soetikno V, Kodama M, Aizawa Y: Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr Cardiol Rev. 2010, 6: 280-290. 10.2174/157340310793566145.PubMed CentralView ArticlePubMed
- Sourris KC, Harcourt BE, Tang PH, Morley AL, Huynh K, Penfold SA, Coughlan MT, Cooper ME, Nguyen TV, Ritchie RH, Forbes JM: Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type2 diabetes. Free Radic Biol Med. 2012, 52: 716-723. 10.1016/j.freeradbiomed.2011.11.017.View ArticlePubMed
- Wold LE, Ceylan-Isik AF, Ren J: Oxidative stress and stress signaling: menace of diabetic cardio myopathy. Acta Pharmacol Sin. 2005, 26: 908-917. 10.1111/j.1745-7254.2005.00146.x.View ArticlePubMed
- Dikalov S: Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med. 2011, 51: 1289-1301. 10.1016/j.freeradbiomed.2011.06.033.PubMed CentralView ArticlePubMed
- Doughan AK, Harrison DG, Dikalov SI: Molecular mechanisms of angiotensin II mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008, 102: 488-496. 10.1161/CIRCRESAHA.107.162800.View ArticlePubMed
- Maisch B, Alter P, Pankuweit S: Diabetic cardiomyopathy-fact or fiction?. Herz. 2011, 36: 102-115. 10.1007/s00059-011-3429-4.View ArticlePubMed
- Mashimo K, Sato S, Ohno Y: Chronic effects of ethanol on cultured myocardial cells: ultrastructural and morphometric studies. Virchows Arch. 2003, 442: 356-363.PubMed
- Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP: Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation. 2007, 115: 909-917. 10.1161/CIRCULATIONAHA.106.662296.PubMed CentralView ArticlePubMed
- Gulick T, Cresci S, Caira T, Moore DD, Kelly KP: The peroxisome proliferator activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A. 1994, 91: 11012-11016. 10.1073/pnas.91.23.11012.PubMed CentralView ArticlePubMed
- Falcão-Pires I, Leite-Moreira AF: Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev. 2012, 17: 325-344. 10.1007/s10741-011-9257-z.View ArticlePubMed
- Sack MN: Type 2 diabetes, mitochondrial biology and the heart. J Mol Cell Cardiol. 2009, 46: 842-849. 10.1016/j.yjmcc.2009.02.001.PubMed CentralView ArticlePubMed
- Duncan JG: Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta. 1813, 2011: 1351-1359.
- Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000, 404: 787-790. 10.1038/35008121.View ArticlePubMed
- Huynh K, McMullen JR, Julius TL, Tan JW, Love JE, Cemerlang N, Kiriazis H, Du XJ, Ritchie RH: Cardiac-specific insulin-like growth factor 1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes. 2010, 59: 1512-1520. 10.2337/db09-1456.PubMed CentralView ArticlePubMed
- Hardie DG, John WS, David AP, Emma RH: Management of cellular energy by the AMP activated protein kinase system. FEBS Lett. 2003, 546: 113-120. 10.1016/S0014-5793(03)00560-X.View ArticlePubMed
- Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005, 1: 15-25. 10.1016/j.cmet.2004.12.003.View ArticlePubMed
- Saha AK, Ruderman NB: Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem. 2003, 253: 65-70. 10.1023/A:1026053302036.View ArticlePubMed
- Saha AK, Schwarsin AJ, Roduit R, Masse F, Kaushik V, Tornheim K, Prentki M, Ruderman NB: Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta -Dribofuranoside. J Biol Chem. 2000, 275: 24279-24283. 10.1074/jbc.C000291200.View ArticlePubMed
- Ruderman N, Prentki M: AMP kinase and malonyl-CoA: targets for therapy of themetabolic syndrome. Nat Rev Drug Discov. 2004, 3: 340-351. 10.1038/nrd1344.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.